Granisetron
- Generic Name
- Granisetron
- Brand Names
- Sancuso, Sustol
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24N4O
- CAS Number
- 109889-09-0
- Unique Ingredient Identifier
- WZG3J2MCOL
- Background
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
- Indication
For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
- Associated Conditions
- Nausea and vomiting
- Associated Therapies
- -
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT01536392
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon B. Johnson General Hospital, Houston, Texas, United States
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 1369
- Registration Number
- NCT01500226
- Locations
- 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 555
- Registration Number
- NCT01500213
- Locations
- 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT01499849
- Locations
- 🇺🇸
TESARO Inc, Waltham, Massachusetts, United States
Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT01352130
- Locations
- 🇮🇳
Tata Memorial Hopsital, Mumbai, Maharashtra, India
Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 19
- Registration Number
- NCT01183481
- Locations
- 🇨🇦
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 421
- Registration Number
- NCT00952341
Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT00890565
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT00873197
- Locations
- 🇬🇧
Charles River Clinical Services Edinburgh Ltd, Edinburgh, United Kingdom
An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT00868764
- Locations
- 🇬🇧
Charles River Clinical Services Edinburgh Ltd, Edinburgh, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.